Bringing artificial intelligence (AI) to the development of small molecule therapies for amyotrophic lateral sclerosis (ALS) and other neurological diseases is the goal of a business partnership in Asia. The newly signed agreement is between Insilico Medicine, an AI-driven drug discovery company based in Hong Kong, and 4B Technologies of Suzhou,…

Dropping the levels of microRNA-218 (miR-218) — a small molecule that regulates the activity of other genes — below a certain threshold leads to severe motor neuron damage, paralysis, and death in a mouse model of amyotrophic lateral sclerosis (ALS), a study shows. The findings, combined with the fact that…

A national agency in Norway has given AB Science the go-ahead to resume enrollment in AB19001, a Phase 3 clinical trial investigating the safety and efficacy of the company’s investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS). AB had voluntarily suspended recruitment and treatment…

Mast cells, a type of immune cell, infiltrate the spinal cord of amyotrophic lateral sclerosis (ALS) patients and rodent models of the disease, exhibiting pro-inflammatory features that are likely involved in motor neuron and microvasculature damage, a study suggests. Notably, treating these mice models with masitinib — an experimental oral…

Eledon Pharmaceuticals announced that its Phase 2 study of AT-1501 in people with amyotrophic lateral sclerosis (ALS) should be fully enrolled by year’s end. Top-line trial results are expected between April and September 2022. “Enrollment in our ALS study is progressing well and we anticipate completing enrollment in…

I AM ALS, a nonprofit dedicated to helping people affected by amyotrophic lateral sclerosis (ALS), is expanding its efforts in scientific research and public policy. The organization’s new Science and Policy program will include three key focuses, according to a press release emailed to ALS News Today.

A Temple University research team received a National Institutes of Health (NIH) grant totaling $1.25 million to explore the molecular underpinnings of neuronal degeneration in amyotrophic lateral sclerosis (ALS) and other diseases. With this five-year grant, the team led by Gareth Thomas, PhD, an associate professor of neural sciences…

Alexion Pharmaceuticals is stopping further work on Ultomiris (ravulizumab) — its approved therapy for complement-associated rare blood disorders — as a potential treatment of amyotrophic lateral sclerosis (ALS) based on interim data from the CHAMPION-ALS Phase 3 clinical trial. While top-line results were expected by mid-2022, the study’s independent data…

People affected by amyotrophic lateral sclerosis (ALS) have come up with plenty of creative ways to raise money for research and care — whether it’s the ALS Ice Bucket Challenge, re-creating Olympic events, or Major League Baseball’s designation of June 2 as Lou Gehrig Day. Joe…

MediciNova is still recruiting adults with early-stage amyotrophic lateral sclerosis (ALS) for the COMBAT-ALS Phase 2b/3 clinical trial evaluating its investigational oral therapy MN-166 (ibudilast). Patients are being enrolled at 19 sites across North America; more information about contacts and locations is available here. “We continue to…